Trial · NCT03683225
A Study to Evaluate in Patients With Parkinsonian Type Disorders
NCT03683225, Phase 2, Unknown, Chase Therapeutics Corporation
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Evaluate in Patients With Parkinsonian Type Disorders. Trials, record NCT03683225. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03683225
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate in Patients With Parkinsonian Type Disorders
- NCT number
- NCT03683225
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Chase Therapeutics Corporation
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- CTC-413
- First posted
- 2018-09-25
- Last updated
- 2024-07-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse Events | multiple times for the duration of the study (baseline through Month 3) | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0" . Incidence and nature of adverse events; vital signs; |
| Primary | Number of participants with change in weight | mulitple times from baseline through Month 3 | Number of participants with a change in weight (either by pounds or kilograms) from baseline |
| Primary | Number of participants with change in in physical examine | multiple times for the duration of the study (baseline through Month 3) | physical examination changes General appearance,Head, eyes, ears, nose, and throat, Respiratory, Cardiovascular, Musculoskeletal, Abdomen, Neurologic, Extremities, Dermatologic, Lymphatic) |
| Primary | Number of participants with change in in clinical laboratory evaluations | multiple times for the duration of the study (baseline through Month 3) | changes in clinical laboratory evaluations (Creatinine, Potassium(K+),Sodium (Na+) , Chloride (Cl-), Magnesium (Mg++), Calcium, Inorganic phosphate, Glucose, Urea,Bilirubin (Total) ,Bilirubin (direct), AST, ALT, GGT, Alkaline phosphatase, Total Protein Albumin, |
| Primary | Number of participants with change in Electrocardiography (ECG) | multiple times for the duration of the study (baseline through Month 3) | ECG (standard digital 12-lead in singlicate). |
| Secondary | Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | multiple times from baseline through Month 3 | Change from baseline in the MDS-UPDRS Part 4 for motor fluctuations and dyskinesia severity will be assessed hourly x3 on assessment days.motor complications (six items). Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Total score 0-24. |
| Secondary | modified Columbia-Suicide Severity Rating Scale | multiple times from baseline through Month 3 | 3 question scale to to gage is the subject is having suicidal tendencies. If the response is "YES" to Question 1 or 2, or if the response to Question 3 reveals a concern about a significant level of suicidality, the subject would undergo a more detailed assessment by a qualified clinician who has experience in the evaluation of suicidal ideation and behavior, either at the site or by referral to an outside clinician. In either case, appropriate documentation of the clinical issues and management plan will be required in a narrative that would be placed in the subject's study record. Questions are 'yes' or 'no' |
| Secondary | Pharmacokinetics of pramipexole and aprepitant | multiple times from baseline through Month 3 | Plasma concentrations of pramipexole and aprepitant will be measured |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03683225
GET https://conductscience.org/api/trials/v1/NCT03683225/registered